Pas de connexion internet — affichage de la version enregistrée de la page.

Sarepta Therapeut…

USUSD
← Vers le screener
US:SRPTLSE:0L35

Sarepta Therapeutics Inc (US:SRPT) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site web
sarepta.com
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège social
Cambridge, United States
PDG
Michael E. Severino
Employés
835
Fondée
1980
Actions en circulation
105.63 M au 2026-07-31
Flottant
100.54 M
Capitalisation boursière
1.86 Md USD
Initiés
4.89%
Investisseurs institutionnels
104.07%
Secteur d'activité (SIC)
Pharmaceutical Preparations
ISIN
US8036071004
LEI
549300IKDPIED8J8IG21
Taux de distribution
0%
FCF
81.8 M USD
Dette
848 M USD
3.4 ans de FCF
Ancienneté du dividende
—
Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 30.06.2026 (le dernier rapport de l'entreprise).
Description

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Bourses et tickers

BourseTickerDevisePrixType
US USA StocksSRPT principaleUSD18.21 +4.06%actions ordinaires
LSE London Stock Exchange0L35 IOBUSD18.0173 +0.00%actions ordinaires

Cours sur 3 mois

jour de hausse jour de baisse date de détachement du dividende date de versementSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Dividendes

Aucun versement de dividendes n'a été trouvé (vérifié le 10.10.2026). L'entreprise ne verse probablement pas de dividendes.

Actualités de cette semaine

Pas encore d'actualités du site de l'entreprise.

publicité

Principaux actionnaires

DétenteurParticipationActionsDate du rapport
Blackrock Inc.17.98%18.99 M2026-06-30
State Street Corporation8.44%8.92 M2026-06-30
Vanguard Portfolio Manag…7.93%8.38 M2026-06-30
iShares Trust-iShares Co…6.09%6.44 M2026-08-31
First TRT Exch-Trd Fd.-F…4.52%4.78 M2026-08-31
SPDR SERIES TRUST-State…4.45%4.7 M2026-08-31
Two Sigma Investments, L…4.35%4.6 M2026-06-30
Vanguard Capital Managem…4.35%4.59 M2026-06-30
First Trust Advisors LP4.13%4.37 M2026-06-30
AQR Capital Management,…4.1%4.33 M2026-06-30
BARRY RICHARD J (Directo…≈3.06%3.23 M2026-06-04
VANGUARD INDEX FUNDS-Van…3.02%3.19 M2026-06-30
Geode Capital Management…2.62%2.77 M2026-06-30
iShares Trust-iShares Ru…2.52%2.66 M2026-08-31
Erste Asset Management G…2.43%2.57 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.17%2.3 M2026-06-30
Marshall Wace LLP2.09%2.21 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.26%1.33 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.14%1.2 M2026-06-30
Fidelity Salem Street Tr…1.08%1.14 M2026-07-31
Federated Hermes Equity…1.05%1.11 M2026-07-31
INGRAM DOUGLAS S (Chief…≈0.88%929 3912025-12-05
SEVERINO MICHAEL E (Chie…≈0.72%756 1042026-07-28
CHAMBERS MICHAEL ANDREW…≈0.48%504 0272026-06-04
RODINO-KLAPAC LOUISE (Of…≈0.22%227 6702026-02-27
BEHRENS M KATHLEEN (Dire…≈0.21%224 3572026-06-04
ESTEPAN IAN MICHAEL (Chi…≈0.19%204 6992026-02-27
ROTHFUSS CRISTIN (Genera…≈0.13%139 9852025-09-03
WONG RYAN HO-YAN (Chief…≈0.13%136 2032025-09-03
NICAISE CLAUDE (Director…≈0.05%48 4072026-06-04